Bristol-Myers Squibb Boosted by Blood Thinner Study

Bristol-Myers Squibb BMY shares are rising today after the release of a study which shows that an experimental blood-thinning drug co-produced by BMY and Pfizer PFE cut the rate of strokes among people with abnormal heartbeats by more than 50% versus aspirin. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on BMY. To read the rest, head over to BloggingStocks.